BRAVNETSA (lutetium lu-177 dotatate) · LANTHEUS MEDICAL
BRAVNETSA is FDA-approved to treat 1 condition (same as LUTATHERA).
Details
- Status
- Prescription
- First Approved
- 2026-09-21
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
Latest BRAVNETSA News
All BRAVNETSA news →BRAVNETSA Approval History
What BRAVNETSA Treats
1 indicationsBRAVNETSA is approved for 1 conditions since its original approval in 2026. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Gastroenteropancreatic Neuroendocrine Tumors
Same approved indications as LUTATHERA (same active ingredient).
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BRAVNETSA FDA Label Details
Indications & Usage
BRAVNETSA is FDA-approved to treat 1 condition — same approved indications as LUTATHERA.
Track BRAVNETSA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.